Oral administration of phytocomponent p-hydroxycinnamic acid has a preventive effect on bone loss in streptozotocin-induced diabetic rats.
The phytocomponent p-hydroxycinnamic acid (HCA) has been shown to have a stimulatory effect on bone formation and an inhibitory effect on bone resorption in rat femoral tissues in vitro. The preventive effect of HCA on bone loss induced in streptozotocin (STZ)-diabetic rats was investigated in vivo. Rats received a single subcutaneous administration of STZ (6.0 mg/100 g body weight), and then the animals were orally administered HCA (0.25, 0.5, or 1.0 mg/100 g body weight) once daily for 14 days. STZ administration caused a significant decrease in body weight and a significant increase in serum glucose, triglyceride, and calcium levels, indicating a diabetic state. These alterations were significantly prevented by administration of HCA (0.25, 0.5, or 1.0 mg/100 g). Calcium content in the femoral-diaphyseal and -metaphyseal tissues was significantly decreased in STZ-diabetic rats. This decrease was significantly prevented after administration of HCA (0.25, 0.5, or 1.0 mg/100 g). Alkaline phosphatase activity in the diaphyseal and metaphyseal tissues was significantly decreased in STZ-diabetic rats. The decrease in diaphyseal alkaline phosphatase activity in STZ-diabetic rats was significantly prevented after administration of HCA (0.5 and 1.0 mg/l00 g). The diaphyseal DNA content was also significantly decreased in STZ-diabetic rats. Administration of HCA (0.25, 0.5, or 1.0 mg/100 g) caused a significant increase in DNA content in the diaphyseal and metaphyseal tissues in STZ-diabetic rats. This study demonstrates that the intake of HCA has preventive effects on bone loss in STZ-diabetic rats, and that the intake has partially restorative effects on serum biochemical findings in the diabetic state.
Yamaguchi
Masayoshi
M
Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Shizuoka, Japan. yamaguch@u-shizuoka-ken.ac.jp
Uchiyama
Satoshi
S
Lai
Ying Ling
YL
D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D001862:Bone Resorption / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D002118:Calcium / Q000378:metabolism; D003373:Coumaric Acids / Q000008:administration & dosage* / Q000627:therapeutic use*; D004247:DNA / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D018483:Diaphyses / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010710:Phosphates / Q000378:metabolism; D008517:Phytotherapy; D028321:Plant Preparations / Q000008:administration & dosage* / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D003373:Coumaric Acids; D010710:Phosphates; D028321:Plant Preparations; D014280:Triglycerides; D013311:Streptozocin; D004247:DNA; D000469:Alkaline Phosphatase; D002118:Calcium